CEO: Neil Kumar

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: Eidos Therapeutics Inc is a clinical development-stage biopharmaceutical company. It is focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.


Key numbers

Market Capitalization:2076936674
Shares Outstanding: 37496600
Float: 8030609
Next Earning Date:2020-04-20
TTm EPS: -0.7947
TTm Dividend Rate:
200 days moving average:39.89
50 days moving average: 56.09
One day percent Change: -0.32



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2016-12-31, 2017-12-31, 2018-12-31,
2016-12-31, 2017-12-31, 2018-12-31,